Paxman AB ( (PXMBF) ) has released its Q3 earnings. Here is a breakdown of the information Paxman AB presented to its investors.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Paxman AB, a leader in scalp cooling technology, is focused on preventing chemotherapy-induced alopecia and neuropathy with innovative solutions for cancer patients worldwide. In its latest earnings report, Paxman showed a 6% increase in sales, reaching 64.8 MSEK in Q3 2024. While net results decreased compared to the previous year, the company achieved positive net cash flow and maintained strong recurring income. Noteworthy developments include a contract with the U.S. Department of Veterans Affairs and the issuance of CPT Category I codes, which are expected to enhance the adoption of Paxman’s insurance-based billing model. Looking ahead, management remains optimistic about continued growth, particularly in the U.S. market, and is committed to advancing its research and development efforts to support sustainable expansion.